2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

ADC-Related Custom Services

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-136952
    p-SCN-Bn-HOPO
    p-SCN-Bn-HOPO is a bifunctional chelator that forms stable octadentate complexes with Zr (IV) and 89Zr4+ via four 1,2-hydroxypyridone groups. p-SCN-Bn-HOPO conjugates with antibodies through the formation of thiourea bonds with lysine residues, and enables efficient 89Zr radiolabeling under mild conditions. p-SCN-Bn-HOPO inhibits bone uptake of free radiometals, stabilizes radiometal-antibody conjugates, and achieves PET imaging with low background and enhanced tumor-to-organ contrast. p-SCN-Bn-HOPO can be used in breast cancer-related research.
    p-SCN-Bn-HOPO
  • HY-159770A
    (S)-EB-FAPI-B2
    (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging.
    (S)-EB-FAPI-B2
  • HY-180447A
    Tz-Ph-PEG4-NH-DOTA tetraTFA
    		98.01%
    Tz-Ph-PEG4-NH-DOTA (Compound 10) tetraTFA is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA tetraTFA can be used in PET imaging and tumor research.
    Tz-Ph-PEG4-NH-DOTA tetraTFA
  • HY-W749627
    NO2A-Butyne
    		98.0%
    NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.
    NO2A-Butyne
  • HY-W717800A
    NO2A-Azide trihydrochloride
    NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.
    NO2A-Azide trihydrochloride
  • HY-P10729
    DOTA-Bombesin (1-14)
    DOTA-Bombesin (1-14) is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-Bombesin (1-14)
  • HY-W011118
    DTPA anhydride
    DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DTPA anhydride
  • HY-P11553B
    DOTA-ECL1i
    		98.06%
    DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.
    DOTA-ECL1i
  • HY-P10239
    Tyr3-Octreotate
    		99.76%
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors.
    Tyr3-Octreotate
  • HY-118635
    Cyprodenate
    		98.0%
    Cyprodenate is an orally active and blood-brain barrier-penetrant stimulant. Cyprodenate can be labeled with 14C. Cyprodenate can be used in the research of psychiatric disorders.
    Cyprodenate
  • HY-134418R
    NOTA (Standard)
    NOTA (Standard) is the analytical standard of NOTA. This product is intended for research and analytical applications. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research.
    NOTA (Standard)
  • HY-136785
    PD151242
    PD151242 is a selective competitive antagonist of the endothelin ETA receptor, with KD values of 0.65 nM, 0.64 nM and 1.92 nM for human, rat and porcine receptors, respectively, and a KD value of 104 μM for the human ETβ receptor. When radiolabeled as [125I]-PD151242, PD151242 can be used to visualize and localize renal vascular ETA receptors.
    PD151242
  • HY-164589
    NOPO
    NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NOPO
  • HY-183766
    HYF038
    HYF038 is a blood-brain barrier-penetrant ligand of apoptosis signal-regulating kinase 1 (ASK1). When labeled with 11C, HYF038 can be used for ASK1 neuroimaging studies.
    HYF038
  • HY-138134
    NOTP
    NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.
    NOTP
  • HY-P5520
    GB-6
    GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects.
    GB-6
  • HY-167791
    DOTA-PEG4-TFP
    DOTA-PEG4-TFP is a conjugate of the chelating agent DOTA (HY-W053583) and a linker. DOTA-PEG4-TFP can be used in the synthesis of radionuclide compounds.
    DOTA-PEG4-TFP
  • HY-P11845
    DOTA-NT-20.3-IPBA
    DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [68Ga]Ga.
    DOTA-NT-20.3-IPBA
  • HY-183600
    SCN-PYTA
    SCN-PYTA is a bifunctional chelator for trivalent radiometals. After conjugation with monoclonal antibodies, SCN-PYTA forms a stable complex with 225Ac to achieve efficient radiolabeling. SCN-PYTA can be used in cancer research.
    SCN-PYTA
  • HY-156991
    NODAGA-NHS
    NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma.
    NODAGA-NHS
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.